B of A Securities Maintains Buy on Denali Therapeutics, Lowers Price Target to $28

Benzinga · 03/10 16:52
B of A Securities analyst Tazeen Ahmad maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and lowers the price target from $30 to $28.